Lv3
206 积分 2026-06-02 加入
Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)
23天前
已完结
NFkappaB selectivity of estrogen receptor ligands revealed by comparative crystallographic analyses
1个月前
已完结
Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
1个月前
已完结
Effect of ESR1 Somatic Mutations on SERM/SERD Binding: Insights from Molecular Docking and Molecular Dynamics Simulations
1个月前
已完结
The PROTAC milestone: FDA approval of vepdegestrant (ARV-471) for ESR1-mutated breast cancer
1个月前
已完结
Selective Estrogen receptor degraders (SERDs) for the treatment of breast cancer: An overview
1个月前
已完结
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences
1个月前
已完结
[Effect of ESR1 Somatic Mutations on SERM/SERD Binding: Insights from Molecular Docking and Molecular Dynamics Simulations]
1个月前
已关闭
[Lasofoxifene, a next generation estrogen receptor modulator: preclinical studies]
1个月前
已关闭
Drug discovery of N-methyl-pyrazole derivatives as potent selective estrogen receptor degrader (SERD) for the treatment of breast cancer
1个月前
已完结
皖公网安备34019202002308
